Menu
Not yet recruiting NCT05875649

A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure

— Observational AML

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: CLAG.
Who it may be relevant to
Registry conditions: AML. Basic parameters: 14 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Most of patients with acute myeloid leukemia achieved complete remission (CR) after primary induction chemotherapy, there were 20-30% patients without CR after first-induction. It was uncertain how to treat these patients. It was investigated in our study that these patients were re-induced with CLAG Regimen. The CR ratio, overall survival (OS) and relapsed-free survival (RFS) was statistically analysed in these patients.

Interventions

  • Combination product CLAG
    Acute myeloid leukemia patients are re-induced by CLAG Regimen after first-induction failure

Primary outcome measures

  • Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction failure [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • Acute myeloid leukemia patients with first-induction failure

Exclusion criteria

  • Acute myeloid leukemia patients with serious infection and organ dysfunction.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

China · 2 centers
  • Nanfang Hospital of Southern Medical University — Guanzhou
  • Nanfang Hospital of Southern Medical University — Guanzhou

Identifiers

NCT: NCT05875649 · NEFC-2023-162

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗